相关实验视频

Updated: Aug 1, 2026

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

结直肠癌的预后建模基于与氧化压力相关的基因

Xiao-Yan Wu¹, Zheng Zhu², Mei-Hua Gai³

¹Center for General Practice Medicine, Nursing Department, Department of Gastroenterology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China.

Journal of cancer research and clinical oncology

|June 10, 2023

概括

这项研究开发了一种新型模型,使用与氧化压力相关的基因来预测结肠癌预后和免疫反应. 这些发现为诊断和免疫治疗提供了新的生物标志物,有助于临床决策.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
免疫学免疫学免疫学

背景情况:

结肠癌是一种常见的消化道恶性瘤.
与氧化压力相关的基因可能会影响瘤的免疫微环境和治疗反应.
这些基因对结肠癌预后和免疫特征的确切影响需要进一步调查.

研究的目的:

为了研究氧化压力相关基因在结肠癌的预后意义.
探索基因表达与瘤免疫微环境之间的关联.
开发一款用于结肠癌管理中的临床决策的预测模型.

主要方法:

使用了癌症基因组图谱 (TCGA) 数据集.
使用步骤和考克斯回归分析构建了一个签名模型和名图.
分析了基因表达对免疫透,微卫星不稳定性 (MSI) 和药物敏感性的影响.

主要成果:

开发的签名模型和名图显示了结肠癌的强烈预后潜力.
发现基因表达与各种免疫细胞高度相关.
确定了SRD5A1,GSR,TXN,TRAF2和TRAP1作为潜在的诊断生物标志物和免疫治疗指标.

结论:

新型的签名模型和包含氧化压力相关基因的名图为临床决策提供了有价值的工具.
这些发现突出了氧化应激基因在塑造结肠癌免疫格局中的作用.
特定的基因 (SRD5A1,GSR,TXN,TRAF2,TRAP1) 显示为结肠癌诊断和免疫治疗反应的生物标志物具有前途.

关键词:

大肠癌是什么意思大肠癌是什么意思这个名字叫做Nomogram.氧化应激是一种氧化应激.签名签名签名签名

更多相关视频

Analyzing Oxidative Stress in Murine Intestinal Organoids using Reactive Oxygen Species-Sensitive Fluorogenic Probe

Analyzing Oxidative Stress in Murine Intestinal Organoids using Reactive Oxygen Species-Sensitive Fluorogenic Probe

Published on: September 17, 2021

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...